TY  - JOUR
AU  - Benavides, M
AU  - Alcaide-Garcia, J
AU  - Torres, E
AU  - Gil-Calle, S
AU  - Sevilla, I
AU  - Wolman, R
AU  - Duran, G
AU  - Alvarez, M
AU  - Reyna-Fortes, C
AU  - Ales, I
AU  - Pereda, T
AU  - Robles, M
AU  - Kushnir, M
AU  - Odegaard, J
AU  - Faull, I
AU  - Alba, E
PY  - 2022
DO  - 10.1016/j.esmoop.2022.100481
UR  - http://hdl.handle.net/10668/22215
T2  - ESMO open
AB  - Comprehensive biomarker testing is essential in selecting optimal treatment for patients with metastatic colorectal cancer (mCRC); however, incomplete genotyping is widespread, with most patients not receiving testing for all guideline-recommended...
LA  - en
PB  - Elsevier
KW  - Biomarker
KW  - Circulating tumor DNA
KW  - Genomic profiling
KW  - Liquid biopsy
KW  - Metastatic colorectal cancer
KW  - Next-generation sequencing
KW  - Circulating Tumor DNA
KW  - Colonic Neoplasms
KW  - Colorectal Neoplasms
KW  - Genotype
KW  - Humans
KW  - Liquid Biopsy
KW  - Standard of Care
TI  - Clinical utility of comprehensive circulating tumor DNA genotyping compared with standard of care tissue testing in patients with newly diagnosed metastatic colorectal cancer.
TY  - research article
VL  - 7
ER  -